No black box warning on record for Amtagvi

As of the latest FDA labeling reviewed, Amtagvi (LIFILEUCEL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Amtagvi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: Monitor for hypersensitivity reactions during infusion ( 5.8 ) 5.1 Treatment-Related Mortality AMTAGVI is associated with treatment-related mortality. In the clinical trial, the treatment-related mortality rate was 7.5% (N=160), including 2 deaths during the lymphodepleting period, 6 deaths within 30 days, and 4 deaths 38 to 150 days following

No black box warning on record for Amtagvi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: Monitor for hypersensitivity reactions during infusion ( 5.8 ) 5.1 Treatment-Related Mortality AMTAGVI is associated with treatment-related mortality. In the clinical trial, the treatment-related mortality rate was 7.5% (N=160), including 2 deaths during the lymphodepleting period, 6 deaths within 30 days, and 4 deaths 38 to 150 days following

Amtagvi Black Box Warning

No black box warning on record for Amtagvi

Other warnings & precautions

Amtagvi Black Box Warning

No black box warning on record for Amtagvi

Other warnings & precautions